Biology Reference
In-Depth Information
47. Smith A, Tyrell D, Coyle K, Higgins P. Effects of interferon alpha on performance in man:
a preliminary report. Psychopharmacology 1988;96:414-16.
48. Lloyd AR, Hickie I, Boughton CR, Spencer O, Wakefield D. Prevalence of chronic fatigue
syndrome in an Australian population. Med J Aust 1990;153:522-28.
49. Lloyd A, Hickie I, Wakefield D. Immunity and the pathophysiology of chronic fatigue
syndrome. Ciba Found Symp 1993;173:176-92.
50. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic
fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med
1994;121:953-59.
51. White PD. Fatigue and chronic fatigue syndromes. In: Bass CM, editor. Somatization:
physical symptoms and psychological stress. Oxford: Blackwell; 1996. p. 104-40.
52. Dickinson CJ. Chronic fatigue syndrome—aetiological aspects. Eur J Clin Invest
1997;27:257-67.
53. Hickie I, Lloyd A, Hadzi-Pavlovic D, Parker G, Bird K, Wakefield D. Can the chronic
fatigue syndrome be defined by distinct clinical features? Psychol Med 1995;25:925-35.
54. Renault PF, Hoofnagel JH. Side effects of alpha interferon. Semin Liver Dis 1989;9:273-77.
55. Daugherty SA, Henry B, Peterson DL, Swarts RL, Bastien S, Thomas RS. Chronic fatigue
syndrome in northern Nevada. Rev Infect Dis 1991;13:S39-44.
56. Barker E, Fujimura SF, Fadem MB. Immunological abnormalities associated with chronic
fatigue syndrome. Clin Infect Dis 1994;18:S136-41.
57. Konstantinov K, Von Mikecz A, Buchwald D, Jones J, Gerace L, Tan EM. Autoantibodies
to nuclear envelope antigens in chronic fatigue syndrome. J Clin Invest 1996;98:1888-96.
58. Chao CC, Janoff EN, Hus S, Thomas K, Gallagher M, Tsang M, et al. Altered cytokine
release in peripheral blood mononuclear cell cultures from patients with chronic fatigue
syndrome. Cytokine 1991;3:292-98.
59. Lloyd A, Hickie I, Brockman A, Dwyer J, Wakefield D. Serum and cerebrospinal fluid
cytokine levels in patients with chronic fatigue syndrome and control subjects. J Infect
Dis 1991;164:1023-24.
60. Linde A, Andersson B, Svensson SB, Ahrne H, Carlsson M, Forsberg P, et al. Serum lev-
els of lymphokines and soluble cellular receptors in primary Epstein-Barr virus infection
and in patients with chronic fatigue syndrome. J Infect Dis 1992;165:994-1000.
61. Lloyd A, Gandevia S, Brockman A, Hales J, Wakefield D. Cytokine production and
fatigue in patients with chronic fatigue syndrome and healthy control subjects in response
to exercise. Clin Infect Dis 1994;18:5142-46.
62. Lever AML, Lewis DM, Bannister BA, Fry M, Berry N. Interferon production in postviral
fatigue syndrome. Lancet 1988;i:101.
63. Scott F, Hickie I, Lovric K. Autoimmune disease in patients hospitalised with depressive
disorders. In: Husband A, editor. Central nervous system and immune interactions. New
York: CRC Press; 1993. p. 79-86.
64. Musselman DL, Lawson DH, Gummick JF, Manatung AK, Penna S, Goodkin RS, et al.
Paroxetine for the prevention of depression induced by high-dose interferon-alpha. N Engl
J Med 2001;344:961-66.
65. Castanon N, Leonard BE, Neveu PJ, Yirmiya R. Effects of antidepressants on cytokine
production and actions. Brain Behav Immun 2002;16:569-74.
66. Irwin M. Psychoneuroimmunology of depression: clinical implications. Brain Behav
Immun 2002;16:1-16.
67. Wright CE, Strike PC, Brydon L, Steptoe A. Acute inflammation and negative mood:
mediation by cytokine activation. Brain Behavior and Immunity (2005) 19, 345-350
68. Rabin BS, Cunnick JE, Lysle DT. Stress induced alteration of immune function. Prog
Neuroendocrinol 1990;3:116-24.
